TEAM
Mary J.C. Hendrix, Ph.D.
President, Shepherd University
Dr. Hendrix currently serves as President of Shepherd University. She obtained her Ph.D. from George Washington University in anatomy, followed by postdoctoral training at Harvard Medical School. Dr. Hendrix has served on the NIH Council of Councils, the National Advisory Council for Human Genome Research, the National Cancer Institute (NCI) Board of Scientific Advisors, and currently serves on the Board(s) of Directors for: the Chicago Council on Science and Technology; Research!America; Meritus Medical Center; Annenberg Center for Health Sciences at Eisenhower Medical Center; the National Disease Research Interchange; and the Executive Advisory Board for Northwestern University Center of Cancer Nanotechnology Excellence. She was previously President and Chief Scientific Officer of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and the former Deputy Director and Associate Director of Basic Research at the Holden Comprehensive Cancer Center, University of Iowa. Hendrix has written more than 280 publications on biomedical research and holds 16 patents in the space of cancer diagnostics and therapy. Her research focuses on discovering new therapeutic strategies to inhibit cancer metastasis.
Du-Shieng Chien, Ph.D.
President and CEO, TaiRx, Inc.
Dr. Chien is the founder and President of TaiRx, Inc. He received his Ph.D. in Biopharmaceutics and Pharmacokinetics from the University of Iowa, College of Pharmacy. He has many years of research and management experience in drug development during his time as the Senior Principle Scientist with Allergan and Bayer and as the Director of Pharmacokinetics of Neurogen. In 2002, he returned to Taiwan and joined the National Health Research Institutes as the Associate Director of the Division of Biotechnology and Pharmaceutical Research. He later served as the President and CEO of SunTen Phytotech. In 2010, he established Efficient Pharma Management Corp. to provide services in technical and regulatory consultation and project management for biotech industry. Efficient Pharma Management and Formosa Laboratories later formed TaiRx in 2011. Dr. Chien has since served as the President and CEO of the company. He was also appointed as the President and CEO of TaiRx US, Inc. since 2022.
Yi-Wen Chu, Ph.D.
Senior VP, TaiRx, Inc.
Dr. Chu, the co-founder of TaiRx, Inc., received her Ph.D. in Cancer Biology from University of Arizona. Her scientific specialty is molecular and cellular mechanism of cancer metastasis. She has more than 20 years of experience in research and management of scientific affairs. Dr. Chu served as the Chief of Planning and Evaluation Office, and Associate Director of Intramural Research Affairs at the National Health Research Institutes. She later joined SunTen Phytotech as Vice President, responsible for the management of new drug development programs and business development prior to establish the Efficient Pharma Management Corp. with Dr. Chien in 2010 and served as the President and CEO of the company. She now serves as the Senior Vice President in TaiRx, managing the company operation and strategic development.
Chih-Hua Frank Shen, Ph.D.
President and CEO, Efficient Pharma Management Corp.
Dr. Shen received his Ph.D. from Temple University. Before his position as the President and CEO of Efficient Pharma Management Corp, he served as the Vice President of Data & Statistical Sciences, GPRD, at AbbVie Inc. During this period, Dr. Shen led 400 quantitative scientists worldwide to support global drug discovery and development. Prior to join AbbVie/Abbott, he was the co-founder of Roche Global Pharma Development Center in China (PDCC) based in Shanghai and Asia-Pacific Biometrics Head. Dr. Shen also spent 12 years at Bristol-Myers Squibb (BMS) where he was the Executive Director of Global Biometric Sciences. At the same time, Dr. Shen was also a member of both the BMS Clinical Science Committee and the Development Excellence Council that review clinical protocols and governing process in clinical operations.